Securities code: 688488 securities abbreviation: Jiangsu Aidea Pharmaceutical Co.Ltd(688488) Announcement No.: 2022-016
Jiangsu Aidea Pharmaceutical Co.Ltd(688488)
Explanation and verification opinions of the board of supervisors on the publicity of the list of incentive objects first granted by the company’s restricted stock incentive plan in 2022
The board of supervisors and all supervisors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) (hereinafter referred to as “the company”) held the 21st Meeting of the first board of directors and the 17th meeting of the first board of supervisors on January 19, 2022, deliberated and adopted the proposal on the company’s restricted stock incentive plan in 2022 (Draft) and its summary and other relevant proposals. In accordance with the company law of the people’s Republic of China (hereinafter referred to as the “company law”), the securities law of the people’s Republic of China (hereinafter referred to as the “Securities Law”), the measures for the administration of equity incentive of listed companies (hereinafter referred to as the “administrative measures”) and the Listing Rules of Shanghai Stock Exchange on the science and Innovation Board (hereinafter referred to as the “Listing Rules”) The company publicized the list of incentive objects granted for the first time by the restricted stock incentive plan in 2022 in the company according to the relevant laws, regulations and normative documents such as the self regulatory guide for listed companies on the science and Innovation Board No. 4 – disclosure of equity incentive information and the relevant provisions of the Jiangsu Aidea Pharmaceutical Co.Ltd(688488) articles of Association (hereinafter referred to as the “articles of association”), The board of supervisors of the company checked the incentive objects granted for the first time in combination with the publicity. The relevant publicity and verification are announced as follows:
1、 Publicity and verification methods
1. Publicity
The company was posted on the website of Shanghai Stock Exchange (www.sse. Com. CN.) on January 20, 2022 Disclosed the Jiangsu Aidea Pharmaceutical Co.Ltd(688488) 2022 restricted stock incentive plan (Draft) (hereinafter referred to as the “incentive plan (Draft)”) and its summary Management measures for the implementation and assessment of Jiangsu Aidea Pharmaceutical Co.Ltd(688488) 2022 restricted stock incentive plan and the list of incentive objects first granted by Jiangsu Aidea Pharmaceutical Co.Ltd(688488) 2022 restricted stock incentive plan (hereinafter referred to as the “list of incentive objects”) and other documents.
The company publicized the names and positions of the proposed incentive objects within the company from January 21, 2022 to January 30, 2022. The publicity period is 10 days in total. The employees of the company can give feedback to the board of supervisors during the publicity period.
As of the expiration of the publicity period, the board of supervisors of the company has not received any objection to the proposed incentive object. 2. Verification methods of the board of supervisors of the company on the proposed incentive objects
Check the identity documents of the incentive objects who have signed the incentive contract with the company or the subsidiary of the company, and the list of the incentive objects who are proposed to be employed in the company or the employment agreement with the subsidiary of the company.
2、 Verification opinions of the board of supervisors
In accordance with the relevant provisions of the administrative measures, listing rules and incentive plan (Draft) and the publicity, the board of supervisors of the company issued the following verification opinions:
1. The personnel listed in the list of incentive objects in this incentive plan have the qualifications specified in the company law, securities law, administrative measures and other laws, regulations and normative documents as well as the articles of association.
2. The proposed incentive object does not have the situation that it is not allowed to become an incentive object as stipulated in the administrative measures: (1) it has been identified as an inappropriate candidate by the stock exchange in the last 12 months;
(2) In the last 12 months, it has been identified as an inappropriate candidate by the CSRC and its dispatched offices;
(3) Being administratively punished by the CSRC and its dispatched offices or taking market entry prohibition measures for major violations of laws and regulations in the last 12 months;
(4) Those who are not allowed to serve as directors or senior managers of the company as stipulated in the company law; (5) Those who are not allowed to participate in the equity incentive of listed companies according to laws and regulations;
(6) Other circumstances recognized by the CSRC.
3. The personnel listed in the list of incentive objects of this incentive plan meet the conditions of incentive objects specified in the administrative measures, listing rules and other documents, and meet the scope of incentive objects specified in the incentive plan (Draft). The incentive objects of this incentive plan do not include independent directors and supervisors of the company.
4. The basic information of the proposed incentive object is true, and there is no falsehood, intentional concealment or major misunderstanding.
In conclusion, the board of supervisors of the company believes that the personnel listed in the list of incentive objects of this incentive plan meet the conditions specified in relevant laws, regulations and normative documents and the conditions of incentive objects specified in the incentive plan (Draft), and they are legal and effective as the incentive objects of this restricted stock incentive plan.
It is hereby announced.
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) board of supervisors February 9, 2022
